Market Cap
€65.5b
Last Updated
2020/07/05 20:46 UTC
Data Sources
Company Financials +
Executive Summary
Bayer Aktiengesellschaft operates as a life science company worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer and good value.
Similar Companies
Share Price & News
How has Bayer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BAYN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-0.2%
BAYN
1.6%
DE Pharmaceuticals
2.8%
DE Market
1 Year Return
9.8%
BAYN
12.1%
DE Pharmaceuticals
0.2%
DE Market
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: BAYN exceeded the German Market which returned 0.3% over the past year.
Shareholder returns
| BAYN | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.2% | 1.6% | 2.8% |
| 30 Day | 0.8% | 1.1% | -1.6% |
| 90 Day | 19.5% | 17.5% | 22.0% |
| 1 Year | 14.9%9.8% | 15.7%12.1% | 2.3%0.2% |
| 3 Year | -30.6%-39.4% | 31.6%16.3% | 3.4%-5.0% |
| 5 Year | -39.6%-49.8% | 28.7%6.5% | 11.4%-3.4% |
Price Volatility Vs. Market
How volatile is Bayer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Bayer Aktiengesellschaft's (ETR:BAYN) Stock's Been Going Strong: Could Weak Financials Mean The Market Will Coorect Its Share Price?3 weeks ago | Simply Wall St
Know This Before Buying Bayer Aktiengesellschaft (ETR:BAYN) For Its Dividend1 month ago | Simply Wall St
Bayer (ETR:BAYN) Has A Pretty Healthy Balance SheetValuation
Is Bayer undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAYN (€66.68) is trading below our estimate of fair value (€169.11)
Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAYN is good value based on its PE Ratio (24.7x) compared to the Pharmaceuticals industry average (24.7x).
PE vs Market: BAYN is poor value based on its PE Ratio (24.7x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: BAYN is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: BAYN is good value based on its PB Ratio (1.3x) compared to the DE Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Bayer forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
13.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAYN's forecast earnings growth (13.9% per year) is above the savings rate (0.2%).
Earnings vs Market: BAYN's earnings (13.9% per year) are forecast to grow slower than the German market (22.3% per year).
High Growth Earnings: BAYN's earnings are forecast to grow, but not significantly.
Revenue vs Market: BAYN's revenue (2.8% per year) is forecast to grow slower than the German market (5.9% per year).
High Growth Revenue: BAYN's revenue (2.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAYN's Return on Equity is forecast to be low in 3 years time (14.4%).
Next Steps
Past Performance
How has Bayer performed over the past 5 years?
-17.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAYN has a large one-off loss of €2.9B impacting its March 31 2005 financial results.
Growing Profit Margin: BAYN's current net profit margins (6%) are higher than last year (1.4%).
Past Earnings Growth Analysis
Earnings Trend: BAYN's earnings have declined by -17.6% per year over the past 5 years.
Accelerating Growth: BAYN's earnings growth over the past year (375.4%) exceeds its 5-year average (-17.6% per year).
Earnings vs Industry: BAYN earnings growth over the past year (375.4%) exceeded the Pharmaceuticals industry 15.8%.
Return on Equity
High ROE: BAYN's Return on Equity (5.5%) is considered low.
Next Steps
Financial Health
How is Bayer's financial position?
Financial Position Analysis
Short Term Liabilities: BAYN's short term assets (€33.0B) exceed its short term liabilities (€22.3B).
Long Term Liabilities: BAYN's short term assets (€33.0B) do not cover its long term liabilities (€54.4B).
Debt to Equity History and Analysis
Debt Level: BAYN's debt to equity ratio (79.5%) is considered high.
Reducing Debt: BAYN's debt to equity ratio has reduced from 105.2% to 79.5% over the past 5 years.
Debt Coverage: BAYN's debt is not well covered by operating cash flow (17.8%).
Interest Coverage: BAYN's interest payments on its debt are well covered by EBIT (5.3x coverage).
Balance Sheet
Next Steps
Dividend
What is Bayer current dividend yield, its reliability and sustainability?
4.20%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BAYN's dividend (4.2%) is higher than the bottom 25% of dividend payers in the German market (1.26%).
High Dividend: BAYN's dividend (4.2%) is in the top 25% of dividend payers in the German market (3.83%)
Stability and Growth of Payments
Stable Dividend: BAYN's dividends per share have been stable in the past 10 years.
Growing Dividend: BAYN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (103.7%), BAYN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BAYN's dividends in 3 years are forecast to be well covered by earnings (38.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Werner Baumann (58yo)
4.17yrs
Tenure
€7,461,000
Compensation
Mr. Werner Baumann has been Chairman of the Board of Management and Chief Executive Officer at Bayer AG since May 1, 2016 and has been its Member of Management Board since January 1, 2010. Mr. Baumann serv ...
CEO Compensation Analysis
Compensation vs Market: Werner's total compensation ($USD8.39M) is above average for companies of similar size in the German market ($USD5.36M).
Compensation vs Earnings: Werner's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Management & CEO | 4.17yrs | €7.46m | no data | |
| CFO & Member of Management Board | 2.08yrs | €3.22m | no data | |
| Member of Management Board | 4.5yrs | €4.41m | no data | |
| Head of Consumer Health Division & Member of Management Board | 2.33yrs | €3.53m | no data | |
| President of Pharmaceuticals Division & Member of the Board of Management | 1.67yrs | €4.03m | no data | |
| Head of Accounting and Head of Taxes | 4.25yrs | no data | no data | |
| Head of Investor Relations | 3.33yrs | no data | no data | |
| Head of Law | no data | no data | no data | |
| Head of Communications | 4.17yrs | no data | no data | |
| Head of Mergers | no data | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: BAYN's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 18.25yrs | €204.00k | no data | |
| Member of Supervisory Board | 4.25yrs | €275.00k | no data | |
| Chairman of Executive Board - Bayer Business Services | no data | no data | no data | |
| Member of Supervisory Board | 13.75yrs | €135.00k | no data | |
| Vice Chairman of Supervisory Board | 5yrs | €270.00k | no data | |
| Chairman of Executive Board - Currenta | no data | no data | no data | |
| Member of Supervisory Board | 0.25yr | no data | no data | |
| Member of Supervisory Board | 8.25yrs | €205.00k | no data | |
| Member of Supervisory Board | 8.25yrs | €137.00k | no data | |
| Chairman of Supervisory Board | 0.25yr | €290.00k | no data |
6.6yrs
Average Tenure
63yo
Average Age
Experienced Board: BAYN's board of directors are considered experienced (6.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.
Top Shareholders
Company Information
Bayer Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bayer Aktiengesellschaft
- Ticker: BAYN
- Exchange: XTRA
- Founded: 1863
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €65.508b
- Shares outstanding: 982.42m
- Website: https://www.bayer.com
Number of Employees
Location
- Bayer Aktiengesellschaft
- Kaiser-Wilhelm-Allee 1
- Leverkusen
- North Rhine-Westphalia
- 51368
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BAYR.Y | OTCPK (Pink Sheets LLC) | SPON ADR-EACH REPR 1 ORD NPV | US | USD | Dec 1972 | |
| BAYA | DB (Deutsche Boerse AG) | SPON ADR-EACH REPR 1 ORD NPV | DE | EUR | Dec 1972 | |
| BAYA | XTRA (XETRA Trading Platform) | SPON ADR-EACH REPR 1 ORD NPV | DE | EUR | Dec 1972 | |
| BAYZ.F | OTCPK (Pink Sheets LLC) | Yes | Registered Shares | US | USD | Jan 1975 |
| 0P6S | LSE (London Stock Exchange) | Yes | Registered Shares | GB | EUR | Jan 1975 |
| BAYN | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYN | SWX (SIX Swiss Exchange) | Yes | Registered Shares | CH | CHF | Jan 1975 |
| BAY | BIT (Borsa Italiana) | Yes | Registered Shares | IT | EUR | Jan 1975 |
| BAYN | XTRA (XETRA Trading Platform) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYER | BUSE (Budapest Stock Exchange) | Yes | Registered Shares | HU | HUF | Jan 1975 |
| BAYND | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Registered Shares | GB | EUR | Jan 1975 |
| BAYN N | BMV (Bolsa Mexicana de Valores) | Yes | Registered Shares | MX | MXN | Jan 1975 |
| BAYN | WBAG (Wiener Boerse AG) | Yes | Registered Shares | AT | EUR | Jan 1975 |
| BAY1 | DB (Deutsche Boerse AG) | NPV (NEW) | DE | EUR | Jan 2018 |
Biography
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/05 20:46 |
| End of Day Share Price | 2020/07/03 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.